LabVantage Solutions and The Netherlands Forensic Institute (NFI) Partner to Advance Digital Transformation in Forensic Science
4.12.2024 13:30:00 CET | Business Wire | Press release
—New Collaboration Enhances NFI’s IT Infrastructure with Advanced LIMS to Streamline Workflows, Improve Data Integrity, and Optimize Forensic Operations—
LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS platforms enabling rapid deployment at reduced costs, and The Netherlands Forensic Institute (NFI) today jointly announced a partnership to digitalize forensic laboratory workflows as part of NFI’s IT renewal initiative. A key aspect of this collaboration is the implementation of LabVantage Solutions’ Laboratory Information Management System (LIMS), which is designed to streamline NFI’s forensic operations by replacing fragmented processes and incorporating advanced capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204274659/en/

(Graphic: Business Wire)
NFI’s IT renewal initiative aims to modernize its infrastructure by replacing outdated manual systems with streamlined, automated workflows. Currently, the workflows involve multiple manual registrations across different systems, which can lead to time-consuming tasks and potential inconsistencies. The integration of LabVantage LIMS will unify data entry and enhance traceability, ensuring that data is efficiently recorded and utilized. It will also improve overall clarity and operational efficiency across forensic investigations, saving valuable time for all involved.
Peter Blom, Chief Information Officer of NFI, expressed his enthusiasm for the project: “This partnership marks a significant milestone in our journey to innovate and improve our forensic services. By integrating a sophisticated LIMS, we are setting a new standard in forensic science.”
“We are proud to work alongside NFI in their mission to enhance forensic operations,” said Michel Gerlicher, President, LabVantage International. “This collaboration will bring about a new era of efficiency and reliability in their laboratory workflows.”
The project includes contributions from Protinus, which served as the IT broker, and Capgemini, which is developing the sovereign cloud infrastructure to host the LIMS. The new system will integrate seamlessly into NFI’s operations, ensuring compliance with stringent security standards while enabling forensic experts to work faster and more confidently. By leveraging a secure, sovereign cloud infrastructure, the partnership will meet the highest standards of data protection and regulatory compliance, including BIO (Baseline Information Security for Government) and BBN (Baseline Information Security for Enterprises) requirements.
Alan Marcus, Chief Growth Officer at LabVantage Solutions, emphasized the broader implications of this alliance: “We are excited to see the real-life impact our investments in industry-specific solutions bring to our clients. With Software-as-a-Service (SaaS) becoming the de facto delivery standard, we expect vertical solutions to prove increasingly impactful, allowing clients to benefit from the latest innovations without being held back by past adaptations required by industry-agnostic software. NFI’s validation that our forensics solutions are fit for purpose is encouraging, and we are humbled to contribute to the fact-finding mission of NFI’s world-leading forensic laboratories.”
LabVantage Solutions, in joint effort with Protinus and Capgemini, will ensure the new system is secure and fully compliant with all required standards. By implementing LabVantage LIMS, NFI will streamline processes, enhance data accuracy, and improve data management, reinforcing its commitment to innovation and reliability. This partnership strengthens NFI’s role as a leader in delivering reliable forensic services to organizations around the world, while further establishing LabVantage Solutions’ prominence in the enterprise laboratory software solutions industry.
To learn more about LabVantage Solutions’ end-to-end informatics solutions for the complete forensic life cycle, please visit labvantage.com or contact us here.
About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. Its highly configurable, 100% browser-based platform consists of LIMS, ELN, LES, SDMS, and advanced analytics, supporting seamless deployment into any environment. Serving over 1,500 customers across life sciences, pharmaceuticals, biobanking, food & beverage, forensics, and more, LabVantage Solutions empowers innovation, helps improve product quality, and ensures compliance with industry regulations. Headquartered in Somerset, NJ, with offices worldwide, LabVantage Solutions has driven laboratory digital transformation for over 40 years. For more information, visit labvantage.com.
About The Netherlands Forensic Institute (NFI):
The Netherlands Forensic Institute is dedicated to providing high-quality forensic services to support justice, peace, and security. The NFI has achieved this position by constantly improving its products and services. Science and innovation at the NFI are strongly driven by experiences from forensic practice. Through this innovative approach and commitment to excellence, the NFI serves both national and international clients, offering a wide range of forensic products and services. For more information, visit https://www.forensischinstituut.nl/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204274659/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom